|
Dr Xavier Hébuterne from France evaluated the efficacy of certolizumab pegol (CZP) in improving endoscopic lesions in patients with active ileocolonic Crohn's disease.
The team performed a phase IIIB multicenter open-label clinical trial, and enrolled 89 adult patients with active endoscopic disease.
Patients received subcutaneous certolizumab pegol 400 mg at weeks 0, 2 and 4, and every 4 weeks up to week 52.
The researchers found that endoscopic evaluations were performed at weeks 0, 10 and 54.
The team's primary outcome was mean change in CDEIS score at week 10.
Secondary outcome measures included endoscopic response, complete remission and mucosal healing at weeks 10 and 54.  | | Endoscopic response at week 10 was 54% | | Gut |
The team of doctors observed that the mean CDEIS score was 15 at baseline. The researchers noted that the mean decrease in CDEIS score at week 10 was 6.
Rates of endoscopic response, endoscopic remission, complete endoscopic remission and mucosal healing at week 10 were 54%, 37%, 10% and 4%, respectively.
The researchers found that that at week 54 the corresponding rates were 49%, 27%, 14% and 8%, respectively.
The safety profile was consistent with that of previous certolizumab pego trials. Dr Xavier and team concludes, "Following certolizumab pego treatment in patients with active Crohn's disease, endoscopic lesions were improved as shown by the decrease in mean CDEIS score and by endoscopic response and remission rates." "These benefits were achieved as early as week 10 and were generally maintained through week 54."
| 
Email this page to a colleague
